Industry
Biotechnology
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Loading...
Open
1.25
Mkt cap
26M
Volume
92K
High
1.29
P/E Ratio
-1.05
52-wk high
4.59
Low
1.21
Div yield
N/A
52-wk low
1.15
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:13 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 12:14 pm
Portfolio Pulse from Avi Kapoor
April 29, 2024 | 5:04 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 11:57 am
Portfolio Pulse from Avi Kapoor
April 12, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
April 12, 2024 | 10:43 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.